These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 20171982)

  • 21. Diet associated with exercise improves baroreflex control of sympathetic nerve activity in metabolic syndrome and sleep apnea patients.
    Toschi-Dias E; Trombetta IC; Silva VJD; Maki-Nunes C; Cepeda FX; Alves MJNN; Carvalho GL; Drager LF; Lorenzi-Filho G; Negrão CE; Rondon MUPB
    Sleep Breath; 2019 Mar; 23(1):143-151. PubMed ID: 29948856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.
    Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW
    Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A; Lundsgaard C
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diet and exercise in obstructive sleep apnea patients with obesity: I'll breathe to that!
    Gozal D
    Obesity (Silver Spring); 2015 Aug; 23(8):1526-7. PubMed ID: 26180039
    [No Abstract]   [Full Text] [Related]  

  • 25. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease.
    Patel SB; Reams GP; Spear RM; Freeman RH; Villarreal D
    Curr Hypertens Rep; 2008 Apr; 10(2):131-7. PubMed ID: 18474180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The underlying mechanisms for development of hypertension in the metabolic syndrome.
    Yanai H; Tomono Y; Ito K; Furutani N; Yoshida H; Tada N
    Nutr J; 2008 Apr; 7():10. PubMed ID: 18416854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diet and exercise improve chemoreflex sensitivity in patients with metabolic syndrome and obstructive sleep apnea.
    Maki-Nunes C; Toschi-Dias E; Cepeda FX; Rondon MU; Alves MJ; Fraga RF; Braga AM; Aguilar AM; Amaro AC; Drager LF; Lorenzi-Filho G; Negrão CE; Trombetta IC
    Obesity (Silver Spring); 2015 Aug; 23(8):1582-90. PubMed ID: 26148219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomedicine. A sympathetic defense against obesity.
    Dulloo AG
    Science; 2002 Aug; 297(5582):780-1. PubMed ID: 12161638
    [No Abstract]   [Full Text] [Related]  

  • 29. The sympathetic nervous system and obesity: role in aetiology and treatment.
    Snitker S; Macdonald I; Ravussin E; Astrup A
    Obes Rev; 2000 May; 1(1):5-15. PubMed ID: 12119646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risk of adipokines: a review.
    Dutheil F; Gordon BA; Naughton G; Crendal E; Courteix D; Chaplais E; Thivel D; Lac G; Benson AC
    J Int Med Res; 2018 Jun; 46(6):2082-2095. PubMed ID: 28974138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited.
    da Silva AA; do Carmo JM; Li X; Wang Z; Mouton AJ; Hall JE
    Can J Cardiol; 2020 May; 36(5):671-682. PubMed ID: 32389340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin resistance and the sympathetic nervous system.
    Egan BM
    Curr Hypertens Rep; 2003 Jun; 5(3):247-54. PubMed ID: 12724058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.
    Carnagarin R; Tan K; Adams L; Matthews VB; Kiuchi MG; Marisol Lugo Gavidia L; Lambert GW; Lambert EA; Herat LY; Schlaich MP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome.
    Grassi G
    Hypertens Res; 2006 Nov; 29(11):839-47. PubMed ID: 17345783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease.
    Esler M; Kaye D
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S1-7. PubMed ID: 11346214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome.
    Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Karapanagiotidis S; Wong C; Richards K; Marusic P; Dixon JB; Schlaich MP; Lambert EA
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1701-7. PubMed ID: 24937541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology of essential hypertension: an update.
    Saxena T; Ali AO; Saxena M
    Expert Rev Cardiovasc Ther; 2018 Dec; 16(12):879-887. PubMed ID: 30354851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High blood pressure management: potential benefits of I1 agents.
    Esler M
    J Hypertens Suppl; 1998 Aug; 16(3):S19-24. PubMed ID: 9747906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex differences in sympathetic activity in obesity and its related hypertension.
    Fu Q
    Ann N Y Acad Sci; 2019 Oct; 1454(1):31-41. PubMed ID: 31087350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity.
    Frigolet ME; Torres N; Tovar AR
    J Nutr Biochem; 2013 Dec; 24(12):2003-15. PubMed ID: 24120291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.